Issue Date: October 1, 2011
Issued by: Center for Biologics Evaluation and Research
Topic(s): Cellular & Gene Therapy, Gene Therapy, Vaccines, Good Clinical Practice (GCP)
Status: Final
Clinical Considerations for Therapeutic Cancer Vaccines: Guidance for Industry
This guidance provides sponsors who wish to submit an Investigational New Drug application (IND) for a therapeutic cancer vaccine with recommendations on critical clinical considerations for investigational studies of these products. This guidance will discuss considerations common to phase 1 and phase 2 clinical trials (collectively referred to as “early phase clinical trials”) and phase 3 clinical trials (referred to as “late phase clinical trials”), as well as considerations that are unique to specific stages of clinical development of therapeutic cancer vaccines. This guidance provides recommendations for the design of clinical trials for cancer vaccines conducted under an IND (Title 21 Code of Federal Regulations (21 CFR) Part 312) to support a subsequent biologics license application (BLA) for marketing approval. This guidance finalizes the draft guidance of the same title dated September 2009.
Download the Guidance Document
